bevacizumab-awwb vs IBI305

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

bevacizumab-awwb · MVASI

Marketed by Amgen and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT01966003 · Phase 3 · completed

This randomized, quadruple-blind, active-controlled Phase 3 trial in 642 patients with advanced non-small cell lung cancer compared the biosimilar bevacizumab-awwb with reference bevacizumab, both added to chemotherapy. Objective response rates were closely matched (39.0% vs 41.7%), and the prespecified statistical test showed the two products were clinically equivalent.

Reported efficacy

Percentage of Participants With an Objective Response (Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively.): Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results). (met)

Result source: NCT01966003

IBI305

Marketed by Innovent Biologics

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02954172 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 450 enrolled participants (220 and 221 in the reported primary analysis groups). Its primary clinical endpoint, objective response rate at 18 weeks, met the prespecified equivalence criterion: 44.3% with IBI305 versus 46.4% with bevacizumab, with the 90% confidence interval for the odds ratio entirely within the 0.75–1.33 equivalence margin.

Reported efficacy

Objective Response Rate (18 weeks): Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33. (met)

Result source: NCT02954172

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbevacizumab-awwbIBI305
PFS, median6.6 vs 7.9vs Bevacizumabn 328NCT019660038.4 vs 8.3vs Bevacizumabn 221NCT02954172
OS, median—Not reported18.0n 221NCT02954172
ORR39% vs 41.7%vs Bevacizumabn 328NCT0196600344.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT02954172
Duration of response, median5.8 vs 5.6vs Bevacizumabn 128NCT01966003—Not reported

PFS, median

bevacizumab-awwb
6.6 vs 7.9vs Bevacizumabn 328NCT01966003
IBI305
8.4 vs 8.3vs Bevacizumabn 221NCT02954172

OS, median

bevacizumab-awwb
—Not reported
IBI305
18.0n 221NCT02954172

ORR

bevacizumab-awwb
39% vs 41.7%vs Bevacizumabn 328NCT01966003
IBI305
44.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT02954172

Duration of response, median

bevacizumab-awwb
5.8 vs 5.6vs Bevacizumabn 128NCT01966003
IBI305
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. bevacizumab-awwb: 3 of 4 rows · IBI305: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbevacizumab-awwbIBI305
Dropout rate
82.3%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
1.3%a
NCT02954172 · Phase 3 · combination
Discontinued due to AEs
—
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—a
NCT02954172 · Phase 3 · combination
Serious AEs
26.2%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
33.5%a
NCT02954172 · Phase 3 · combination
Most frequent reported AEs
alopecia 43.2%
nausea 25.3%
anaemia 20.1%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
a
white blood cell count decreased 71.9%
neutrophil count decreased 70.5%
platelet count decreased 50.4%
NCT02954172 · Phase 3 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

bevacizumab-awwb

Duration of Response 5.8 vs 5.6 Bevacizumab months
time to event · months
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bevacizumab-awwb's landscape · IBI305's landscape